Advaxis Study in Head and Neck Cancer Selected for Late-Breaking Poster at the American Association for Cancer Research Annual Meeting

PRINCETON, N.J., March 02, 2016  -- Advaxis, Inc. (ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a Phase 2 study of its lead Lm immunotherapy candidate in HPV-associated head and neck cancer, axalimogene filolisbac (AXAL), has been selected as a late-breaker poster presentation at the American Association for Cancer Research (AACR) Annual Meeting. According to AACR’s selection criteria, late-breaking abstracts demonstrate highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline. Additionally, only abstracts deemed to be of high scientific priority are accepted for presentation.

EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437

WALTHAM, Mass., March 02, 2016 -- Eyegate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has received an additional development milestone from Valeant Pharmaceuticals Luxembourg S.à.r.l. (“Valeant”) under the Company’s License Agreement with Valeant for the development and commercialization of the Company’s EGP-437 combination product in the field of uveitis.

The Company is eligible to receive milestone payments totaling up to $32.5 million upon and subject to the achievement of certain specified developmental and commercial milestones.

Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea

-- New Allowances Bolster Strong SYN-004 Patent Estate --

ROCKVILLE, Md., March 1, 2016-- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that the U.S. Patent and Trademark Office (USPTO) issued Notices of Allowance for three patent applications which cover composition of matter claims and methods of protecting the gut microbiome from certain beta-lactam antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). These new allowances further strengthen the Company's novel proprietary candidate, SYN-004, which is also covered by a composition of matter patent in the U.S.

Halozyme Reports Fourth Quarter And Full Year 2015 Financial Results

- Investigational device exemption submitted to FDA, on track for first patient dosing in March in Phase 3 Study of metastatic pancreatic cancer patients -
- Growing momentum in ENHANZE™ franchise with recent signing of Lilly collaboration and first dosing in clinical trials with Janssen's Daratumumab, AbbVie's HUMIRA® and Pfizer's Rivipansel and Bococizumab -
- Full year revenue of $135.1 million compared to $75.3 million in prior year, Royalty Revenue of $31 million increased 229 percent from prior year -

SAN DIEGO, Feb. 29, 2016  -- Halozyme Therapeutics, Inc. (HALO) today reported financial results for the fourth quarter and full year ended December 31, 2015, which included a fourth quarter increase in royalty revenue of 136 percent from the prior year period and net income of $4.3 million, or $0.03 per share, compared to a net loss in the fourth quarter of 2014 of $5.3 million, or $0.04 per share.  For the full year, total revenue increased 79 percent to $135.1 million compared to $75.3 million in the prior year.